<DOC>
	<DOCNO>NCT00866736</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety dasatinib subject chronic phase chronic myeloid leukemia ( CML ) either resistant intolerant imatinib mesylate .</brief_summary>
	<brief_title>A Study Dasatinib Patients With Imatinib Resistant Intolerant Chronic Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Signed Written Informed Consent Subjects chronic phase chronic myeloid leukemia ( CML ) Subjects resistant/intolerant imatinib Subjects present : 1 . ECOG performance status ( PS ) score 02 2 . Adequate hepatic function 3 . Adequate renal function 4 . Adequate lung function Concurrent malignancy CML Women pregnant breastfeeding Concurrent pleural effusion Uncontrolled significant cardiovascular disease A serious uncontrolled medical disorder would impair ability subject receive protocol therapy . Prior therapy dasatinib Subjects T315I and/or F317L BCRABL point mutation</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>chronic myeloid leukemia</keyword>
	<keyword>dasatinib</keyword>
	<keyword>chronic phase myeloid leukemia</keyword>
</DOC>